14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
DOOO vs ABOS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DOOO Overall Winner
6-Pillar Tally: DOOO 5 – 1 ABOS
Matrix Metrics: DOOO 9 – 1 ABOS
As of Nov 20, 2026, BRP Inc. Common Subordinate Voting Shares (DOOO) is the stronger overall head-to-head candidate over Acumen Pharmaceuticals, Inc. (ABOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DOOO carries a Unified Composite Score of 64.6/100 (BUY) at $76.20 (14.4x Forward P/E, 4.8% operating margin), whereas ABOS carries 49.2/100 (HOLD) at $0.19 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: DOOO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.2); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DOOO vs ABOS. Trailing 12-month operating profitability (DOOO 4.8% vs ABOS 0.0%) and valuation multiples (DOOO 14.4x vs ABOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Miscellaneous Transportation Equipment value chain with $5.1B market capitalization and 4.8% operating margin.
OpEx & R&D Reinvestment16.4% of Rev ($1.27B)
90D Engineering Disclosures0 Published
ABOS Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $14.0M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DOOO vs ABOS Key Questions & Quantitative Answers
As of Nov 20, 2026, BRP Inc. Common Subordinate Voting Shares (DOOO) is the stronger overall head-to-head candidate over Acumen Pharmaceuticals, Inc. (ABOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DOOO carries a Unified Composite Score of 64.6/100 (BUY) at $76.20 (14.4x Forward P/E, 4.8% operating margin), whereas ABOS carries 49.2/100 (HOLD) at $0.19 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: DOOO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.2); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DOOO leads the Growth & Scale pillar: DOOO posts +4.3% YoY revenue growth and +295.8% YoY earnings growth on $7.75B TTM revenue (21.2% gross margin, 4.8% operating margin), compared with ABOS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $329,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DOOO generates $7.75B in USD-normalized revenue versus $329,000 for ABOS. In operating R&D and SG&A reinvestment, DOOO deploys 16.4% of Rev ($1.27B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABOS.
DOOO screens cheaper on headline valuation multiples. DOOO trades at 14.4x Forward P/E, 36.1x Trailing P/E, 2.04x PEG, and 0.7x EV/Revenue (10.9% EBITDA margin), whereas ABOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DOOO (37.5% ROE) versus ABOS (-162.7% ROE) capital efficiency.
In options market volatility and institutional positioning, DOOO carries 42.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.97β · 39% Vol realized risk). By comparison, ABOS carries 232.4% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.62β · 326% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.